Lao version of venetoclax/venetoclax drug price analysis

Venetoclax/Venetoclax is an innovative targeted therapy drug for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). Recently, a number of generic versions of Venacla from Laos have emerged on the market, produced by well-known pharmaceutical companies such as Laos Lucius Pharmaceuticals, Daxiong Pharmaceuticals, and ASEAN Pharmaceuticals. The core ingredients of these generic drugs are basically the same as the original drugs, with only slight differences in specifications, manufacturers and pricing.

The mechanism of action of venetoclax is that it is a potentBCL-2 inhibitor. BCL-2 protein plays an important role in regulating cell apoptosis in the human body. In CLL, SLL and AML cells, abnormally elevated levels of this protein enhance the survival of these cancer cells and help them resist chemotherapy attacks. Venetoclax can bind tightly to the BCL-2 protein, thereby blocking its function, ultimately leading to the apoptosis of cancer cells. Patients usually feel the effects of the drug within hours after taking venetoclax, although patients may not directly feel the immediate effects of the drug in the absence of obvious tumor lysis syndrome (TLS) symptoms. During treatment, your doctor will perform regular blood tests to assess how well Venetexla is working.

Currently, the generic version of Venacla produced in Laos has not yet been launched in the domestic market, but it may be sold in local medical institutions in Laos. Taking each box containing 100mg*112 tablets as an example, the price fluctuates between RMB 2,000 and RMB 3,000 (please note that the price may fluctuate due to exchange rate changes). For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.